Publications by authors named "K K H Aben"
Article Synopsis
- Obesity during mid-life is linked to a higher risk of renal cell carcinoma (RCC), but obese patients diagnosed with RCC tend to have better survival rates, highlighting an "obesity paradox."
- 334 patients with localized RCC were studied regarding their pre- and post-diagnosis weight changes, revealing an average weight loss of 1.45 kg in the two years leading up to diagnosis.
- Non-obese patients and those with more advanced tumors experienced greater weight loss prior to diagnosis, and a portion of that weight was regained within two years after diagnosis, indicating disease-related weight loss patterns that may explain the obesity paradox.
Objective: To evaluate whether surgical margin status, alongside existing postoperative risk indicators, improves the identification of bladder cancer patients who may benefit from adjuvant therapy following radical cystectomy (RC).
Methods: In this nationwide cohort study, patients aged ≥18 years diagnosed with muscle-invasive bladder cancer (MIBC) without nodal or distant metastasis (cT2-4aN0/xM0) between November 2017 and December 2020 who underwent RC were selected from the Netherlands Cancer Registry. Detailed information on surgical margin status was obtained through linkage with the Dutch central pathology database, Palga.
Purpose: This study examined the associations of device-measured moderate-to-vigorous physical activity (MVPA) and sedentary time as well as self-reported MVPA with health-related quality of life (HRQoL) in patients with localized renal cell cancer (RCC) in the recovery phase after surgery.
Methods: At 3 months post-surgery, 341 patients with stage I-III RCC participating in the ReLife study wore an ActivPAL3 device to determine MVPA and sedentary time. The SQUASH questionnaire was used for assessing self-reported MVPA, and the EORTC QLQ-C30 for assessing HRQoL (range 0-100).
Background: For patients with metastatic bladder cancer (mBC) palliative chemotherapy is one of the main treatment options. Real-world insights into outcomes are available, but a comprehensive overview of specific treatment details like number of chemotherapy cycles received and (reasons for) adjustments is lacking.
Methods: A population-based study was conducted, including all patients diagnosed with mBC in the Netherlands between 2016 and 2021 who started chemotherapy as initial treatment.
Article Synopsis
- This study focuses on understanding and predicting clinically relevant fatigue (CRF) in cancer patients two to three years after diagnosis, aiming to enhance supportive care for clinicians.
- Researchers examined data from 3160 patients with various cancer types, using both traditional logistic regression and advanced machine learning models to identify factors associated with CRF.
- While the logistic regression model showed good discrimination between patients with and without CRF, it also indicated potential underdiagnosis, raising concerns about the clinical applicability of the models used.